Navigation Links
Valeant Pharmaceuticals Prices Public Offering Of Common Shares
Date:6/18/2013

nnection with the Offering  the intended use of proceeds and the acquisition and financing of B+L. Forward looking statements can generally be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "should," "would," "intend," "seem," "potential," "appear," "continue," "future," believe," "estimate," "forecast," "project," variations of such words or other words that convey uncertainty of future events or outcome, although not all forward-looking statements contain these identifying words. Our forward-looking statements are subject to known and unknown risks and uncertainties, many of which are outside of our control and could cause actual results to differ materially and adversely from those expressed or implied by such statements. Those risks include, but are not limited to: our future economic performance, operating results, financial condition, capital resources or prospects; projections of revenue, expenses, income and losses, earnings (losses) per share, capital expenditures, dividends, growth rates or other financial items; market or industry trends, legal or regulatory developments; future events; the anticipated effect of acquisitions, litigation, new (or changes to existing) laws, regulations or accounting principles or other matters on our business, economic performance, operating results, financial condition, capital resources or prospects; our plans, objectives and strategies for future operations or otherwise; and our expectations and beliefs. Information concerning potential factors that could affect the Company's financial results is included in the Company's most recent annual or quarterly report and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The
'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Announces Public Offering Of Common Shares
2. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
3. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
4. Valeant Pharmaceuticals Announces 2013 Annual Meeting Results
5. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
6. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
7. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
8. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
9. Valeant Pharmaceuticals Provides Efinconazole Update
10. Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
11. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 24, 2015 Research ... of the "Global Array Instruments Market 2015-2019" ... global array instruments market to grow at a ... The global array instruments market can be ... and others including tissue microarrays and cell microarrays. ...
(Date:6/30/2015)... 2015  Inari Medical, Inc. announced today that it ... financing. The financing was led by members of the ... US Venture Partners.  The round also included participation by ... very pleased to complete this financing with the support ... , who joined in February 2015 as President and ...
(Date:6/30/2015)... ALISO VIEJO, Calif. , June 30, 2015 ... from the PRISM II study showing that treatment ... statistically significant reduction in symptoms of pseudobulbar affect ... or stroke. PBA is a distressing condition characterized ... crying resulting from certain neurologic diseases or brain ...
Breaking Medicine Technology:Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... MonoSol Rx, the developers of PharmFilm® technology and ... film products, today announced that it held a ... Food and Drug Administration (FDA) regarding the development ... a 505(b)(2) pathway.  The registration dossier of Montelukast ...
... 2011 PTC Therapeutics, Inc. (PTC) today announced the ... Medical Officer.  Dr. Spiegel served previously as Chief Medical ... of Jay Barth, M.D. to Vice President of Clinical ... Spiegel will report to Stuart W. Peltz, Ph.D., President ...
Cached Medicine Technology:MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 2MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film 3PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 2PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 3
(Date:6/30/2015)... , ... June 30, 2015 , ... The American Lung ... at a media event in San Diego. Speakers and clean air advocates included San ... medicine, Natalie Germuska of Kindred Hospital, and Daniel Sullivan, founder and president of Sullivan ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, ... they have been awarded the exclusive billing agreements with Jackson Radiology Associates in ... services encompassing their proprietary suite of billing process software functionality called Experience Based ...
(Date:6/30/2015)... Beach, CA (PRWEB) , ... June 30, 2015 , ... ... Skilled Nursing”, which features multiple patient and family member testimonials. Medicare rated the care ... country. Broadway plans to use the video to give future patients a firsthand look ...
(Date:6/30/2015)... ... 2015 , ... Family and professional dementia caregivers are invited ... 9, 2015 at the Hyatt Regency Denver Tech Center from 7:30 am-4:30 pm. ... Campbell, the wife and daughter of singer Glen Campbell, who will discuss their ...
(Date:6/30/2015)... ... ... Rocky Mountain Oils, a leading non-MLM supplier of premium essential oils, ... Mr. Darold Francis. The changes will help enhance the company’s focus on strict product ... to know and respect for over eight years. , “I am thrilled to join ...
Breaking Medicine News(10 mins):Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 2Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 3Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Family of Singer Glen Campbell to Discuss Living with Dementia at the Alzheimer's Association of Colorado's 26th Annual Education Symposium 2Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2
... and Drug Administration approved naltrexone for the treatment of ... drug therapy available was disulfiram, or Antabuse, which provokes ... sobering doubts on earlier claims that an alcoholism drug ... is sponsoring a large trial comparing naltrexone, which is ...
... Americans living on their own takes a medication that ... According to the report, more than 21% of elderly ... of these 33 potentially inappropriate medications in 1996. ... always avoid, including certain sedatives, long-acting drugs to bring ...
... more likely than women to suffer eyelid droop as they age, ... side and front view photographs// of the eyes of 256 people ... that after the age of 35, the lower eyelid started to ... as women. Sagging is caused by the increased laxity of eyelid ...
... by burning away small amounts of heart tissue is as ... to new research.// The radiofrequency catheter ablation (RFCA) treatment involves ... - into the area of the heart which is struggling ... mild painless burst of radiofrequency energy, similar to microwave heat, ...
... the bed for sleep and sex rather than popping sedatives, ... pills worked in the// short-term, but only changing their behaviour ... defined as trouble falling asleep, waking frequently in the night ... to get back to sleep.Less than 15% get any treatment ...
... to impotence have prompted one in eight viewers to get ... about the drug and possible side effects. TV commercials for ... Administration set up rules and made them legal. // ... effect -- nearly a third of adults have talked to ...
Cached Medicine News:Health News:Cure for sleepless nights 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: